ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

Recruiting now · Phase 2

Conditions studied: Liver Metastases

In brief

To determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.

Key facts

Study ID

NCT05062317

Run by

M.D. Anderson Cancer Center

People needed

120

Starts

2022-04-26

Expected to finish

2027-02-28

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients ≥18 years of age with CLM undergoing elective hepatectomy with curative intent (primary colorectal primary cancer previously removed OR being removed at time of hepatectomy) after preoperative chemotherapy (i.e., FOLFOX/FOLFIRI +/- bevacizumab or panitumumab/cetuximab) from 07/01/2021 - 12/31/2023
• Must receive ≥ 4 cycles of preoperative chemotherapy

You may not qualify if…

• Patients with primary colorectal tumor that will remain in situ
• Inability to undergo postoperative chemotherapy, or postoperative chemotherapy not planned a priori
• Unwilling/unable to undergo blood draws for ctDNA, patient or provider-determined
• Other active malignancies requiring treatment
• Women who are pregnant

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.